De Leeuw, I <br/><br/>
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Jan 2005 
 - 73-82 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1462-8902 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1326.2004.00363.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Blood Glucose--analysis<br/>Body Weight--drug effects<br/>Diabetes Mellitus, Type 1--blood<br/>Drug Administration Schedule<br/>Female<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Insulin--administration & dosage<br/>Insulin Detemir<br/>Insulin, Isophane--administration & dosage<br/>Insulin, Long-Acting<br/>Male